Aardvark Therapeutics said it is pausing two Phase 2 trials of its oral obesity asset ARD-201, putting its entire metabolic pipeline on hold. The company cited a comprehensive review of ARD-201 data following an earlier pause of its Phase 3 Prader-Willi syndrome program tied to reversible cardiac observations at above-target doses. ARD-201 combines ARD-101, a gut-targeting taste receptor agonist, with a DPP4 inhibitor, and the paused Phase 2 trials were intended to test weight gain prevention and weight loss in combination with a GLP-1 drug and lifestyle interventions. In recent trading, Aardvark shares had already fallen sharply after the earlier ARD-101 pause. The decision underscores how quickly safety signals and evolving assessments can cascade into broader pipeline suspension, forcing investors to wait for FDA dialogue and updated clinical review outcomes.